Expression Data from transNOAH breast cancer trial

Download

These data can be used for evaluation of the clinical utility of the research-based PAM50 subtype predictor in predicting pathological complete response (pCR) and event-free survival (EFS) in women enrolled in the NeOAdjuvant Herceptin (NOAH) trial. The NeOAdjuvant Herceptin [NOAH] trial demonstrated that trastuzumab significantly improves pCR rates and 3-year event-free survival (EFS) in combination with neoadjuvant chemotherapy compared with neoadjuvant chemotherapy alone in patients with HER2+ breast cancer.

Cancer Type: Breast Cancer

GPL: 570

Number of Genes with Data: 978

Number Observations: 156

Number Outputs: 5

Imbalanced Ratio: 0.857142857

Default Task: Classification